TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
LBRX

LB Pharmaceuticals Inc

Healthcare · Biotechnology

42.50$ +0.8% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns LB Pharmaceuticals Inc (LBRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.0% of the shares are freely tradable; institutional investors hold 106.9%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 106.9%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 82.0%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 19.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 32Mio.

Largest Shareholders

Institutions

Institutions LBRX
Name Stake (%) Shares Change (%) Date
Deep Track Capital, LP 10.39 3,352,804 +0.0 06/30/2026
BlackRock Inc 7.66 2,470,845 +10.4 03/31/2026
RA Capital Management, LLC 6.85 2,208,604 +0.0 03/31/2026
Trails Edge Capital Partners, LP 4.72 1,523,022 +15.4 06/30/2026
COMMODORE CAPITAL LP 4.65 1,500,000 +0.0 03/31/2026
TCG Crossover Management, LLC 4.49 1,447,310 -21.3 06/30/2026
Caligan Partners LP 4.46 1,438,070 +0.0 06/30/2026
JPMorgan Chase & Co 4.43 1,427,568 -11.4 03/31/2026
Spruce Street Capital LP 4.27 1,376,159 +0.0 06/30/2026
Nantahala Capital Management, LLC 3.26 1,052,894 +56.0 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?